aspartic acid has been researched along with Death, Sudden, Cardiac in 3 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with schizophrenia have a two- to three-fold increased risk of premature death as compared to patients without this disease." | 2.46 | Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. ( Arida, RM; Cavalheiro, EA; Cysneiros, RM; Gattaz, WF; Schmitt, A; Scorza, FA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scorza, FA | 1 |
| Schmitt, A | 1 |
| Cysneiros, RM | 1 |
| Arida, RM | 1 |
| Cavalheiro, EA | 1 |
| Gattaz, WF | 1 |
| Hedman, A | 1 |
| Hartikainen, J | 1 |
| Vanninen, E | 1 |
| Laitinen, T | 1 |
| Jääskeläinen, P | 1 |
| Laakso, M | 1 |
| Peuhkurinen, K | 1 |
| Kuusisto, J | 1 |
| Beyersdorf, F | 1 |
| Kirsh, M | 1 |
| Buckberg, GD | 1 |
| Allen, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
1 review available for aspartic acid and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.
Topics: Antipsychotic Agents; Aspartic Acid; Death, Sudden, Cardiac; Epilepsy; Glutamine; Humans; Prefrontal | 2010 |
2 other studies available for aspartic acid and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Inducibility of life-threatening ventricular arrhythmias is related to maximum left ventricular thickness and clinical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomy
Topics: Adult; Angiography; Arrhythmias, Cardiac; Asparagine; Aspartic Acid; Biomarkers; Cardiomyopathy, Hyp | 2004 |
Warm glutamate/aspartate-enriched blood cardioplegic solution for perioperative sudden death.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Cardioplegic Solutions; Cardiopulmonary Resuscitation; Coron | 1992 |